Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Justin Garland und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Hauptthemen laut MEDLINE: HSP70 Heat-Shock Proteins, Uterine Cervical Neoplasms, Papillomavirus E7 Proteins, Oncogene Proteins, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This research was funded by National Cancer Institute., National Cancer Institute.
Abstract (Originalsprache)
Cervical cancer is predominantly driven by persistent infections with high‐risk human papillomavirus and the continuous activity of its E6 and E7 oncoproteins. This study explored the role of heat shock proteins 70 kDa (HSP70s) in enhancing the function of these oncoproteins and examined the impact of SHetA2, an investigational new drug, on this interaction. We found that HSP70 specifically binds to E7, but not E6, protein and that SHetA2 disrupts this binding. This disruption led to a significant reduction in E6 and E7 mRNA and E7 protein levels, while effects on E6 protein levels were minimal. SHetA2 treatment also resulted in altered levels of cell cycle regulatory proteins, reduced cell cycle progression, and decreased metabolic viability in cervical cancer cell lines and xenograft models. These findings support the potential of SHetA2 to impair cervical cancer progression by targeting HSP70/E7 interactions, highlighting its promise as a therapeutic strategy for treating cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
- Division of Molecular Diagnostics and Molecular Oncology, ICMR-National Institute of Cancer Prevention and Research, Noida, India.
- Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
ORCID-Profile: Justin Garland, Showket Hussain, Rajani Rai, Amy L Kennedy, Zitha Redempta Isingizwe, Doris M Benbrook
Förderung
- NCI NIH HHS
- This research was funded by National Cancer Institute.
- National Cancer Institute
Zitieren
APA
Garland, J., Hussain, S., Rai, R., Kennedy, A. L., Isingizwe, Z. R., & Benbrook, D. M. (2024). Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. Journal of Medical Virology. https://doi.org/10.1002/jmv.70088
Vancouver
Garland J, Hussain S, Rai R, Kennedy AL, Isingizwe ZR, Benbrook DM. Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. Journal of Medical Virology. 2024. doi:10.1002/jmv.70088
BibTeX
@article{Garland2024,
author = {Garland, Justin and Hussain, Showket and Rai, Rajani and Kennedy, Amy L and Isingizwe, Zitha Redempta and Benbrook, Doris M},
title = {Targeting HSP70‐E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70088}
}
EUVIMED